Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles
- PMID: 22713718
- DOI: 10.1016/j.vaccine.2012.06.011
Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles
Abstract
Although respiratory syncytial virus (RSV) is the leading cause of serious respiratory tract disease in children, to date no RSV vaccine is available. To produce an effective subunit vaccine, a truncated secreted version of the F protein (ΔF) was expressed in mammalian cells, purified and shown to form trimers. The ΔF protein was then formulated with a CpG oligodeoxynucleotide (ODN) and an innate defense regulator (IDR) peptide in polyphosphazene microparticles (ΔF-MP). Mice immunized either intramuscularly (IM) or intranasally (IN) with ΔF-MP developed significantly higher levels of virus-neutralizing antibodies in the sera and lungs, as well as higher numbers of IFN-γ secreting cells than mice immunized with the ΔF protein alone. In contrast, the IM delivered ΔF induced high production of IL-5 while the IN delivered ΔF did not elicit a measurable immune response. After RSV challenge, essentially no virus and no evidence of immunopathology were detected in mice immunized with ΔF-MP regardless of the route of delivery. While the mice immunized IM with ΔF alone also showed reduced virus replication, they developed enhanced levels of pulmonary IgE, IL-4, IL-5, IL-13 and eotaxin, as well as eosinophilia after challenge. The level of protection induced by the ΔF-MP formulation was equivalent after IM and IN delivery. The efficacy and safety of the ΔF-MP formulation was confirmed in cotton rats, which also developed enhanced immune responses and were fully protected from RSV challenge after vaccination with ΔF-MP. In conclusion, formulation of recombinant ΔF with CpG ODN and IDR peptide in polyphosphazene microparticles should be considered for further evaluation as a safe and effective vaccine against RSV.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?Curr Opin Infect Dis. 2015 Jun;28(3):221-4. doi: 10.1097/QCO.0000000000000161. Curr Opin Infect Dis. 2015. PMID: 25918956 Review.
-
The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies.Vaccine. 2015 Mar 10;33(11):1338-44. doi: 10.1016/j.vaccine.2015.01.041. Epub 2015 Jan 28. Vaccine. 2015. PMID: 25637860
-
Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity.J Gen Virol. 2014 May;95(Pt 5):1043-1054. doi: 10.1099/vir.0.062570-0. Epub 2014 Feb 26. J Gen Virol. 2014. PMID: 24572813
-
The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.Expert Rev Vaccines. 2012 Dec;11(12):1441-57. doi: 10.1586/erv.12.117. Expert Rev Vaccines. 2012. PMID: 23252388 Review.
-
Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice.J Gen Virol. 2009 Aug;90(Pt 8):1892-1905. doi: 10.1099/vir.0.011684-0. Epub 2009 Apr 22. J Gen Virol. 2009. PMID: 19386785
Cited by
-
Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders.J Mol Biol. 2024 Feb 15;436(4):168446. doi: 10.1016/j.jmb.2024.168446. Epub 2024 Jan 17. J Mol Biol. 2024. PMID: 38242283
-
The global burden of lower respiratory infections attributable to respiratory syncytial virus in 204 countries and territories, 1990-2019: findings from the Global Burden of Disease Study 2019.Intern Emerg Med. 2024 Jan;19(1):59-70. doi: 10.1007/s11739-023-03438-x. Epub 2023 Oct 3. Intern Emerg Med. 2024. PMID: 37789183
-
Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection.Front Immunol. 2023 Jun 9;14:1186184. doi: 10.3389/fimmu.2023.1186184. eCollection 2023. Front Immunol. 2023. PMID: 37359514 Free PMC article.
-
Respiratory Syncytial Virus Infection: Treatments and Clinical Management.Vaccines (Basel). 2023 Feb 20;11(2):491. doi: 10.3390/vaccines11020491. Vaccines (Basel). 2023. PMID: 36851368 Free PMC article. Review.
-
A scientometrics study of the nanomedicines assisted in respiratory diseases.Front Bioeng Biotechnol. 2022 Dec 2;10:1053653. doi: 10.3389/fbioe.2022.1053653. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36532565 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical